MOTS-c
Animal / preclinicalAlso known as: Mitochondrial ORF of the 12S rRNA-c
Community-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.
Overview
A mitochondrial-derived peptide that behaves like an exercise mimetic in rodent studies — improving insulin sensitivity, endurance and fat metabolism — with early human trials underway. One of the more scientifically interesting metabolic peptides.
Mechanism
Regulates metabolic homeostasis and insulin sensitivity via AMPK pathways, effectively signalling an exercise-like state in preclinical models.
Evidence
Promising rodent and mechanistic data on metabolism and endurance; human efficacy is where the evidence stops for now.
Community-reported information
Community reports vary. Anecdotal and unvalidated; general information only.
General information only, not tailored to you and not a recommendation. Some regions withhold this entirely.
Half-life
Not well characterised in humans.
Storage
Refrigerate.
Commonly reported side effects
- Not well characterised in humans
Legal status by region
- USNot FDA-approved for human use.
Legal status changes over time; verify locally before relying on this.
Frequently asked questions
- What is MOTS-c?
- A peptide encoded in mitochondrial DNA that acts as a metabolic signal — in rodent studies it improves insulin sensitivity, endurance and fat metabolism, behaving like an exercise mimetic.
- Is there human evidence for MOTS-c?
- Human levels rise with exercise and early clinical work has begun, but the efficacy data so far are rodent and mechanistic. It's a peptide where the science is genuinely moving.